In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism

Randomized, placebo-controlled, double-blind clinical trial

Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B. Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht, Niels Møller, Birgitte Brock, Jørgen Rungby

Research output: Contribution to journalArticle

Abstract

In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMRglc) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide (n = 18), or placebo (n = 20). We measured Aβ load in brain with tracer [11C]PIB (PIB), CMRglc with [18F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment patients (P = 0.04). Regional and global increases of PIB retention did not differ between the groups (P ≥ 0.38). In placebo treated patients CMRglc declined in all regions, significantly so by the following means in precuneus (P = 0.009, 3.2 μmol/hg/min, 95% CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 μmol/hg/min, 95% CI: 4.21; 0.081), temporal (P = 0.046, 1.54 μmol/hg/min, 95% CI: 3.05; 0.030), and occipital (P = 0.009, 2.10 μmol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04, 1.54 μmol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Aβ load or cognition measures, for which the study was underpowered.

Original languageEnglish (US)
Article number108
JournalFrontiers in Aging Neuroscience
Volume8
Issue numberMAY
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 1
Alzheimer Disease
Placebos
Clinical Trials
Glucose
Brain
Cognition
Therapeutics
Incretins
Occipital Lobe
Parietal Lobe
Fluorodeoxyglucose F18
Temporal Lobe
Cerebellum
Animal Models
Hormones

Keywords

  • Alzheimer's disease
  • Amyloid
  • Cerebral glucose metabolism
  • Glucagon-like peptide-1
  • Liraglutide

ASJC Scopus subject areas

  • Aging
  • Cognitive Neuroscience

Cite this

In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism : Randomized, placebo-controlled, double-blind clinical trial. / Gejl, Michael; Gjedde, Albert; Egefjord, Lærke; Møller, Arne; Hansen, Søren B.; Vang, Kim; Rodell, Anders; Brændgaard, Hans; Gottrup, Hanne; Schacht, Anna; Møller, Niels; Brock, Birgitte; Rungby, Jørgen.

In: Frontiers in Aging Neuroscience, Vol. 8, No. MAY, 108, 2016.

Research output: Contribution to journalArticle

Gejl, M, Gjedde, A, Egefjord, L, Møller, A, Hansen, SB, Vang, K, Rodell, A, Brændgaard, H, Gottrup, H, Schacht, A, Møller, N, Brock, B & Rungby, J 2016, 'In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial', Frontiers in Aging Neuroscience, vol. 8, no. MAY, 108. https://doi.org/10.3389/fnagi.2016.00108
Gejl, Michael ; Gjedde, Albert ; Egefjord, Lærke ; Møller, Arne ; Hansen, Søren B. ; Vang, Kim ; Rodell, Anders ; Brændgaard, Hans ; Gottrup, Hanne ; Schacht, Anna ; Møller, Niels ; Brock, Birgitte ; Rungby, Jørgen. / In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism : Randomized, placebo-controlled, double-blind clinical trial. In: Frontiers in Aging Neuroscience. 2016 ; Vol. 8, No. MAY.
@article{bddeecac9d17482f80a440fd0fbce1c5,
title = "In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial",
abstract = "In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMRglc) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide (n = 18), or placebo (n = 20). We measured Aβ load in brain with tracer [11C]PIB (PIB), CMRglc with [18F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment patients (P = 0.04). Regional and global increases of PIB retention did not differ between the groups (P ≥ 0.38). In placebo treated patients CMRglc declined in all regions, significantly so by the following means in precuneus (P = 0.009, 3.2 μmol/hg/min, 95{\%} CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 μmol/hg/min, 95{\%} CI: 4.21; 0.081), temporal (P = 0.046, 1.54 μmol/hg/min, 95{\%} CI: 3.05; 0.030), and occipital (P = 0.009, 2.10 μmol/hg/min, 95{\%} CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04, 1.54 μmol/hg/min, 95{\%} CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Aβ load or cognition measures, for which the study was underpowered.",
keywords = "Alzheimer's disease, Amyloid, Cerebral glucose metabolism, Glucagon-like peptide-1, Liraglutide",
author = "Michael Gejl and Albert Gjedde and L{\ae}rke Egefjord and Arne M{\o}ller and Hansen, {S{\o}ren B.} and Kim Vang and Anders Rodell and Hans Br{\ae}ndgaard and Hanne Gottrup and Anna Schacht and Niels M{\o}ller and Birgitte Brock and J{\o}rgen Rungby",
year = "2016",
doi = "10.3389/fnagi.2016.00108",
language = "English (US)",
volume = "8",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "MAY",

}

TY - JOUR

T1 - In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism

T2 - Randomized, placebo-controlled, double-blind clinical trial

AU - Gejl, Michael

AU - Gjedde, Albert

AU - Egefjord, Lærke

AU - Møller, Arne

AU - Hansen, Søren B.

AU - Vang, Kim

AU - Rodell, Anders

AU - Brændgaard, Hans

AU - Gottrup, Hanne

AU - Schacht, Anna

AU - Møller, Niels

AU - Brock, Birgitte

AU - Rungby, Jørgen

PY - 2016

Y1 - 2016

N2 - In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMRglc) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide (n = 18), or placebo (n = 20). We measured Aβ load in brain with tracer [11C]PIB (PIB), CMRglc with [18F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment patients (P = 0.04). Regional and global increases of PIB retention did not differ between the groups (P ≥ 0.38). In placebo treated patients CMRglc declined in all regions, significantly so by the following means in precuneus (P = 0.009, 3.2 μmol/hg/min, 95% CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 μmol/hg/min, 95% CI: 4.21; 0.081), temporal (P = 0.046, 1.54 μmol/hg/min, 95% CI: 3.05; 0.030), and occipital (P = 0.009, 2.10 μmol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04, 1.54 μmol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Aβ load or cognition measures, for which the study was underpowered.

AB - In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMRglc) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide (n = 18), or placebo (n = 20). We measured Aβ load in brain with tracer [11C]PIB (PIB), CMRglc with [18F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment patients (P = 0.04). Regional and global increases of PIB retention did not differ between the groups (P ≥ 0.38). In placebo treated patients CMRglc declined in all regions, significantly so by the following means in precuneus (P = 0.009, 3.2 μmol/hg/min, 95% CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 μmol/hg/min, 95% CI: 4.21; 0.081), temporal (P = 0.046, 1.54 μmol/hg/min, 95% CI: 3.05; 0.030), and occipital (P = 0.009, 2.10 μmol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04, 1.54 μmol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Aβ load or cognition measures, for which the study was underpowered.

KW - Alzheimer's disease

KW - Amyloid

KW - Cerebral glucose metabolism

KW - Glucagon-like peptide-1

KW - Liraglutide

UR - http://www.scopus.com/inward/record.url?scp=84974559551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974559551&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2016.00108

DO - 10.3389/fnagi.2016.00108

M3 - Article

VL - 8

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - MAY

M1 - 108

ER -